Your prediction
Cerenis Therapeutics Holding S.A. Stock
The Cerenis Therapeutics Holding S.A. stock is trending slightly upwards today, with an increase of €0.020 (0.560%) compared to yesterday's price.
Our community identified positive and negative aspects for Cerenis Therapeutics Holding S.A. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Cerenis Therapeutics Holding S.A. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | 0.560% | -6.510% | 15.064% | 207.890% | 4.665% | 99.223% | 268.962% |
| Sensorion SA | 0.920% | -5.000% | 1.877% | - | - | - | - |
| Genoway S.A. Inh. | 0.870% | 1.304% | -0.427% | -14.022% | -6.048% | -38.032% | -29.819% |
| Hybrigenics S.A. | 0.000% | -7.692% | -14.286% | -60.656% | -7.692% | -95.819% | -98.972% |
News
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced